Neuphoria Therapeutics (NASDAQ:NEUP) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.97) by 90.72 percent. This is a 101.37 percent decrease over earnings of $6.55 per share from the same period last year.